Full Press Release Details
Jaguar Health Reports 2025 Financials
Net revenue increase of 5% in Q4 2025 vs. Q3 2025
Jaguar received an up-front payment of $16M of non-dilutive
capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi and Canalevia -CA1
- Jaguar's commercialized crofelemer drugs - with an additional $2 million due upon completion of post-closing conditions; and has received $3.0 of up to $20 million in milestone payments and other future payments
Agreement with Future Pak is fully aligned with Jaguar's strategy to concentrate crofelemer development efforts on human
rare-disease intestinal failure indications moving forward
Jaguar will appeal Nasdaq's March 5, 2026 noncompliance
determination related to Nasdaq Listing Rule 5550(a)(2) at a hearing on April 7, 2026; delisting is stayed pending the panel's final decision
REMINDER: Friday, April 10, Jaguar to host investor webcast at 8:30 a.m. Eastern regarding Q4 2025 financials and
company updates; Click here to register
SAN FRANCISCO, CA / April 7, 2026 / Jaguar Health, Inc.
(NASDAQ: JAGX) ("Jaguar" or the "Company") today reported its consolidated fourth-quarter 2025 financial results.
FOURTH QUARTER COMPANY FINANCIAL RESULTS:
| Year Ended | ||||||||||||||||
| Financial Highlights | December 31, | |||||||||||||||
| (in thousands, except per share amounts) | 2025 | 2024 | $ change | % change | ||||||||||||
| Net product revenue | $ | 11,511 | $ | 11,689 | (178 | ) | -1.5 | % | ||||||||
| Loss from operations | $ | (45,908 | ) | $ | (30,831 | ) | (15,077 | ) | 32.8 | % | ||||||
| Net loss attributable to common stockholders | $ | (53,575 | ) | $ | (38,492 | ) | (15,083 | ) | 28.2 | % | ||||||
| Net loss per share, basic and diluted | $ | (24.27 | ) | $ | (130.69 | ) | 106 |
| Year Ended | ||||||||||||||||
| December 31, | ||||||||||||||||
| (in thousands) | 2025 | 2024 | $ change | % change | ||||||||||||
| (unaudited) | ||||||||||||||||
| Net loss attributable to common stockholders | $ | (53,575 | ) | $ | (38,492 | ) | 15,083 | -39 | % | |||||||
| Adjustments: | ||||||||||||||||
| Interest income (expense) | 67 | 231 | 164 | 71 | % | |||||||||||
| Property and equipment depreciation | 62 | 67 | 5 | 7 | % | |||||||||||
| Amortization of intangible assets | 1,851 | 1,834 | (17 | ) | -1 | % | ||||||||||
| Share-based compensation expense | 835 | 1,641 | 806 | 49 | % | |||||||||||
| Gain (loss) on extinguishment of debt | 1,799 | (1,245 | ) | (3,044 | ) | 244 | % | |||||||||
| Impairment loss on indefinite-lived intangible assets | 800 | - | 800 | 100 | % | |||||||||||
| Non-GAAP EBITDA | (48,161 | ) | (35,964 | ) | 12,197 | -34 | % |
Note Regarding Use of Non-GAAP Measures
The Company supplements its condensed consolidated financial statements presented on a GAAP basis by providing non-GAAP
EBITDA and non-GAAP recurring EBITDA, which are considered non-GAAP under applicable SEC rules. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects the basis upon which Company management assesses and operates the business. These non-GAAP
financial measures are not in accordance with GAAP and should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss and are not substitutes for, or superior to, measures of financial performance in conformity with GAAP.
The Company defines non-GAAP EBITDA as net loss before interest expense and other expense, depreciation of
property and equipment, amortization of intangible assets, share-based compensation expense and provision for or benefit from income taxes. The Company defines non-GAAP Recurring EBITDA as non-GAAP EBITDA adjusted for certain non-recurring revenues and expenses. Company management believes that non-GAAP EBITDA and non-GAAP Recurring EBITDA are meaningful indicators of Jaguar's performance and provide useful information to investors regarding the Company's results of operations and financial condition.
Participation Instructions for Webcast
When: Friday, April 10, 2026 at 8:30 a.m. Eastern
Participant Registration & Access Link: Click Here
Replay Instructions for Webcast
Replay of the webcast on the investor relations section of Jaguar's website: (click here)
Crofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar
family company, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. ("Jaguar") develops novel proprietary prescription drugs sustainably derived from plants for people with complicated
gastrointestinal ("GI") disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare
and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp, is focused on developing novel
prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Pharmaceuticals, visit napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of
noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are
not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were
upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
See full Prescribing
Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established
a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
GELCLAIR has a mechanical action indicated for the management of pain and relief of pain by adhering
to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including oral mucositis/stomatitis (may be caused by chemotherapy or radiation therapy), irritation due to oral surgery, traumatic ulcers caused by braces or ill-fitting dentures, or disease. Also, indicated for diffuse aphthous ulcers.
IMPORTANT SAFETY INFORMATION
You are encouraged to report negative side effects of prescription medical products to the FDA.
Visit www.fda.gov/safety/medwatch or call
full Prescribing Information at:
Important Safety Information About
For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known
hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for
the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal
law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
See full Prescribing Information at Canalevia.com.
Forward-Looking Statements
Certain statements in this
press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that it will have a hearing on April 7, 2026 with the Nasdaq Hearings Department, and Jaguar's expectation
that it will hold an investor webcast on April 10, 2026. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan,"
"aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict,"
"potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its
current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified
and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events,
changed circumstances or otherwise.
Source: Jaguar Health, Inc.